MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
8.71
+0.05
+0.58%
After Hours: 8.62 -0.09 -1.03% 19:30 12/05 EST
OPEN
8.65
PREV CLOSE
8.66
HIGH
8.79
LOW
8.52
VOLUME
663.94K
TURNOVER
--
52 WEEK HIGH
13.16
52 WEEK LOW
6.19
MARKET CAP
490.35M
P/E (TTM)
14.74
1D
5D
1M
3M
1Y
5Y
1D
Does Zevra Therapeutics’ (ZVRA) Board Turnover Subtly Recast Its Leadership and Capital Allocation Narrative?
Simply Wall St · 2d ago
Zevra Therapeutics (ZVRA): Evaluating Valuation Following High-Profile Board Appointment and CFO Transition
Simply Wall St · 3d ago
Zevra Therapeutics appoints Secor to Board of Directors
TipRanks · 4d ago
Zevra Therapeutics Appoints Alicia Secor to Board as Wendy Dixon Retires
Reuters · 4d ago
ZEVRA THERAPEUTICS, INC. APPOINTS ALICIA SECOR TO BOARD OF DIRECTORS; ANNOUNCES RETIREMENT OF WENDY DIXON, PHD
Reuters · 4d ago
Press Release: Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
Dow Jones · 4d ago
Weekly Report: what happened at ZVRA last week (1124-1128)?
Weekly Report · 5d ago
Zevra Therapeutics (ZVRA): Assessing Valuation After CFO Succession News Spurs Fresh Investor Interest
Simply Wall St · 11/25 11:20
More
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.